Peter RoncoROCKVILLE, MARYLAND, January 16, 2024– BioHealth Innovation, Inc. (BHI), a leading public-private non-profit organization dedicated to advancing healthcare innovation in the BioHealth Capital Region, is pleased to announce the appointment of Peter Ronco to its Board of Directors.

Peter Ronco is an accomplished drug developer and innovative senior pharmaceutical executive, currently serving as the Chief Executive Officer of Emmes, a full-service Contract Research Organization (CRO) operating in 30+ countries and across multiple disease areas, including ophthalmology, vaccines, rare diseases, cell & gene therapy, and neuroscience. With extensive global experience spanning therapeutic areas such as oncology, immunology, neuroscience, vaccines, anti-infectives, cardiovascular, and retinal gene therapy, Peter brings a wealth of knowledge and expertise to the BHI Board.

As CEO of Emmes, Peter is responsible for setting the strategic direction and the organization’s day-to-day operations, which collaborates with over 210 sponsors, including pharmaceutical and biotech companies, government agencies, academic institutions, and non-profit foundations.

Before leading Emmes, Peter was the Head of Global Development at Janssen R&D, overseeing a broad portfolio of 450+ studies across all therapeutic areas and phases. His leadership and innovation were instrumental in the design and execution of groundbreaking drug development programs, including pioneering approaches to trial virtualization, digital health, patient-centered research, and diversity in clinical trials.

“Peter Ronco’s appointment to the BHI Board of Directors is a great way to kick off 2024,” remarked Richard Bendis, President and CEO of BHI. “His exceptional track record in drug development and his commitment to advancing healthcare align perfectly with BHI’s mission to drive innovation in the BioHealth Capital Region.”

Peter Ronco gained experience as Senior Vice President of Global Clinical Operations at Bristol Myers-Squibb and as a consultant with Accenture. He graduated from Nottingham University in the UK and resides in Chester, NJ.

"I am honored to join the BHI Board of Directors and contribute to the advancement of the BioHealth Capital Region," said Peter Ronco, CEO of Emmes & Board Advisor. "With a focus on collaboration and innovation, we have the opportunity to shape the future of this industry and region."Peter’s extensive background and dedication to transformative healthcare solutions make him an invaluable addition to the BHI Board of Directors.

About BioHealth Innovation, Inc.
BioHealth Innovation, Inc. (BHI) is a public-private non-profit organization dedicated to accelerating biohealth (therapeutic, diagnostic, medtech, and health IT) commercialization in the BioHealth Capital Region (Maryland, DC, and Virginia). For more information, please visit